Bacopa Monnieri
C₄₁H₆₈O₁₃
Also known as: Brahmi, Water Hyssop, BacoMind, Synapsa, CDRI-08
Disclaimer: This information is for educational purposes only and is not intended as medical advice. Consult a healthcare professional before starting any supplement regimen.
Molecular Profile
C₄₁H₆₈O₁₃
768.97 g/mol
Bacoside A3 — a dammarane-type triterpenoid saponin representative of the primary active bacoside complex in Bacopa monnieri
157408-08-7
Overview
Bacopa monnieri (Brahmi) is a creeping herb native to the wetlands of India, used for more than 1,500 years in the Ayurvedic tradition to sharpen intellect and aid memory. Modern standardized extracts — most notably Bacognize, BacoMind, CDRI-08 (Synapsa) — are calibrated to a defined bacoside content (typically 45–55% total bacosides) to produce consistent clinical results. Unlike fast-acting stimulants, Bacopa requires daily dosing over 8–12 weeks to reach full effect; the benefits accumulate as the bacosides exert their neurochemical effects on memory consolidation and synaptic plasticity. The molecular data shown represents bacoside A3, a key component of the bacoside A complex that also includes bacopaside II, bacopasaponin C, and bacopaside X. Bacopa is one of the best-evidenced natural nootropics, backed by multiple systematic reviews and meta-analyses.
Mechanism of Action
Bacosides produce their cognitive effects through several convergent actions. They facilitate long-term potentiation in the hippocampus and enhance dendritic length and branching, which supports memory encoding and consolidation. Bacosides modulate cholinergic transmission — bacopa extracts inhibit acetylcholinesterase and increase synaptic acetylcholine — and upregulate BDNF and NGF, supporting neuroplasticity. Antioxidant activity in the hippocampus and prefrontal cortex, chelation of iron, and modulation of serotonergic and dopaminergic systems contribute to its neuroprotective and mood-stabilizing properties. The 8–12 week onset is consistent with these structural/neuroplastic mechanisms rather than acute receptor-level pharmacology.
Benefits & Evidence
Memory Consolidation & Recall
The most robust finding across Bacopa trials: 300–450mg/day of a standardized extract for 8–12 weeks improves delayed word recall, visual information processing, and verbal learning. Effects are strongest on memory acquisition and retention rather than acute memory retrieval.
Anxiety Reduction
Bacopa has mild anxiolytic activity in both preclinical and human studies. In Calabrese 2008, 300mg/day for 12 weeks reduced state anxiety on the STAI alongside cognitive improvements in elderly participants.
Neuroprotection & Antioxidant Activity
Preclinical evidence shows bacosides reduce oxidative stress markers in hippocampal tissue and chelate iron, supporting a neuroprotective role with potential relevance to age-related cognitive decline.
Dosage & Timing
300mg (standardized to 45–55% bacosides)
1x daily
With a meal containing fat — bacosides are fat-soluble. Full effects emerge over 8–12 weeks of daily use.
300mg — 600mg
Note: Only standardized extracts (BacoMind, Bacognize, CDRI-08 / Synapsa) have been validated in clinical trials. Raw powder is not recommended for nootropic use because bacoside content varies enormously. Do not expect acute effects — evaluate at the 8–12 week mark.
Safety Profile
Side Effects
- Gastrointestinal discomfort (nausea, cramping, increased stool frequency — the most common complaint, especially when taken on an empty stomach)
- Dry mouth
- Fatigue or sedation at higher doses
- Mild, transient headache
Interactions
- Acetylcholinesterase inhibitors (donepezil, rivastigmine — additive cholinergic effects)
- Thyroid hormone medications (Bacopa may increase T4 levels in animal studies)
- Sedatives and CNS depressants (mild additive effect)
- Calcium channel blockers (preclinical interaction; clinically uncertain)
Contraindications
- Pregnancy and breastfeeding (insufficient safety data)
- Known thyroid disease (use under clinician supervision)
- Bradycardia or hypotension (use caution)
- Upcoming surgery (discontinue ~2 weeks prior due to mild sedative effects)
References & Sources
The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects
Stough C, Lloyd J, Clarke J, et al.
Psychopharmacology (2001)
Twelve-week double-blind RCT: 300mg/day Bacopa significantly improved speed of information processing, learning rate, and memory consolidation versus placebo in 46 healthy adults.
DOI: 10.1007/s002130100815 ↗Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial
Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B
Journal of Alternative and Complementary Medicine (2008)
Twelve-week trial in 54 adults ≥65 years: 300mg/day Bacopa improved delayed word recall on the AVLT, Stroop, and reduced state anxiety versus placebo.
DOI: 10.1089/acm.2008.0018 ↗Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract
Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Norman Scholfield C
Journal of Ethnopharmacology (2014)
Meta-analysis of nine RCTs (n = 437) concluding that Bacopa monnieri improves cognition, particularly speed of information processing, learning rate, and memory.
DOI: 10.1016/j.jep.2013.09.028 ↗Chronic effects of Brahmi (Bacopa monnieri) on human memory
Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J
Neuropsychopharmacology (2002)
Twelve-week RCT showing Bacopa improved retention of new information on paired-associate learning tasks while leaving short-term memory and attention unchanged.
DOI: 10.1038/sj.npp.1395862 ↗Neuropharmacological review of the nootropic herb Bacopa monnieri
Aguiar S, Borowski T
Rejuvenation Research (2013)
Review synthesizing preclinical and clinical data on Bacopa's antioxidant, cholinergic, dendritic-branching, and memory-enhancing mechanisms.
DOI: 10.1089/rej.2013.1431 ↗